CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy.

The level of CD8+ CD38+ T lymphocytes in blood correlates with disease progression in HIV-infected individuals, independently of the CD4 count. Effective antiretroviral therapy reduces this lymphocyte subset in parallel with plasma viremia, although CD38 expression on CD8+ cells does not normalize completely in most subjects, and might reflect residual HIV replication. The expression of CD38 on CD8+ cells (as number of CD38 molecules per CD8+ cell) was measured quantitatively by flow cytometry in 200 individuals, of whom 170 were HIV positive and 30 were HIV-uninfected controls. Forty-six HIV-infected subjects were on antiretroviral therapy and had undetectable viral load. The remaining 124 HIV-positive persons were not on therapy and had detectable plasma viremia. The mean level of CD38 on CD8+ cells was higher in HIV-positive, untreated patients than in subjects on antiviral therapy and controls (5023, 2029, and 1978 molecules per CD8+ cell, respectively, p < 0.01). In HIV-positive, untreated subjects, the higher CD38 expression mainly occurred on CD45RO+ CD8+ cells. The level of CD38 strongly correlated with plasma HIV-RNA (r = 0.63, p < 0.001). The levels of CD38 on CD8+ cells declined steadily in HIV-positive subjects after beginning antiretroviral therapy. A few individuals presented viral blips whereas being on antiviral treatment, levels of CD38 on CD8+ cells increased transiently in parallel with episodes of viral replication. Levels of CD38 on CD8+ cells are increased in chronic HIV infection, and strongly correlate with plasma viremia. The slow decline of CD38 expression on CD8+ cells over time in subjects with undetectable plasma viremia while being on antiretroviral therapy suggests that CD38 expression on CD8+ cells could be used as a marker of residual virus replication.

[1]  L. Perrin,et al.  Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection , 2002, AIDS.

[2]  J. Benito,et al.  Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users , 2000, AIDS.

[3]  Felipe García,et al.  Comparison of T-cell subsets' reconstitution after 12 months of highly active antiretroviral therapy initiated during early versus advanced states of HIV disease. , 2000 .

[4]  C. Boucher,et al.  The Dominant Source of CD4+ and CD8+ T‐Cell Activation in HIV Infection Is Antigenic Stimulation , 2000, Journal of acquired immune deficiency syndromes.

[5]  A. Landay,et al.  Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease , 2000, AIDS.

[6]  John L. Sullivan,et al.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.

[7]  J. Olofsson,et al.  Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection. , 1999, AIDS.

[8]  J Witek,et al.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 1999, JAMA.

[9]  M. Sinet,et al.  Prospective study of CD8+ lymphocyte activation in relation to viral load in HIV-infected patients with > or = 400 CD4+ lymphocytes per microliter. , 1999, AIDS research and human retroviruses.

[10]  H. Ullum,et al.  Immune function and phenotype before and after highly active antiretroviral therapy. , 1999, Journal of acquired immune deficiency syndromes.

[11]  M. Plana,et al.  Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. , 1999, AIDS.

[12]  D. Cooper,et al.  Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA. , 1999, AIDS research and human retroviruses.

[13]  G. Carcelain,et al.  T cell changes after combined nucleoside analogue therapy in HIV primary infection. , 1999, AIDS.

[14]  A. Perelson,et al.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.

[15]  C. A. Macken,et al.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.

[16]  J V Giorgi,et al.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. , 1999, The Journal of infectious diseases.

[17]  Kaufmann,et al.  Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV‐1 infection correlates with markers of disease severity and changes towards normalization under treatment , 1999, Clinical and experimental immunology.

[18]  R. Weber,et al.  Highly active antiretroviral therapy during early HIV infection reverses T‐cell activation and maturation abnormalities , 1998 .

[19]  C. Boucher,et al.  Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. , 1998, The Journal of infectious diseases.

[20]  R. Detels,et al.  Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV‐1 infection , 1998, AIDS.

[21]  J V Giorgi,et al.  Quantitation of CD38 activation antigen expression on CD8+ T cells in HIV-1 infection using CD4 expression on CD4+ T lymphocytes as a biological calibrator. , 1998, Cytometry.

[22]  R. Detels,et al.  CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[23]  P. Girard,et al.  Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy , 1998, AIDS.

[24]  J. Benito,et al.  Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: changes in the expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR, and CD25 antigens. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[25]  C. Sabin,et al.  CD8+,CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[26]  F. Malavasi,et al.  Human CD38, a cell‐surface protein with multiple functions , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  C. Sabin,et al.  Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. , 1996, AIDS.

[28]  C. Franceschi,et al.  Massive activation of immune cells with an intact T cell repertoire in acute human immunodeficiency virus syndrome. , 1995, The Journal of infectious diseases.

[29]  D. Cooper,et al.  Effects of primary HIV‐1 infection on subsets of CD4+ and CD8+ T lymphocytes , 1995, AIDS.

[30]  H. Prince,et al.  Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. , 1991, Journal of acquired immune deficiency syndromes.

[31]  R. Detels,et al.  T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. , 1989, Clinical immunology and immunopathology.

[32]  A. Abbot,et al.  The Follicular Dendritic Cell: Long Term Antigen Retention During Immunity , 1980, Immunological reviews.